Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 | P30926 | 10/20 | 0.96 |
| ▸ | CHRNA3 | P32297 | 10/20 | 0.96 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.86 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.86 |
| ▸ | THRB | P10828 | 1/20 | 0.86 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.86 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.47 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.47 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6807730 | 1.00 | CHRNB4 (0.96) | CHRNB4CHRNA3ALDH1A1CYP1A2THRB | |
| SCHEMBL6807223 | 1.00 | CHRNB4 (0.96) | CHRNB4CHRNA3ALDH1A1CYP1A2THRB | |
| Anabaseine SCHEMBL261062 | 0.98 | CHRNB4 (1.00) | CHRNB4CHRNA3ALDH1A1CYP1A2THRB | |
| Anabaseine SCHEMBL30394330 | 0.98 | CHRNB4 (1.00) | CHRNB4CHRNA3ALDH1A1CYP1A2THRB | |
| Myosmine SCHEMBL29398376 | 0.93 | ALDH1A1 (1.00) | CHRNB4CHRNA3ALDH1A1CYP1A2THRB | |
| Myosmine SCHEMBL5319476 | 0.93 | ALDH1A1 (1.00) | CHRNB4CHRNA3ALDH1A1CYP1A2THRB | |
| SCHEMBL6797483 | 0.79 | CHRNB4 (0.96) | CHRNB4CHRNA3ALDH1A1CYP1A2THRB | |
| SCHEMBL895500 | 0.77 | CHRNB4 (1.00) | CHRNB4CHRNA3ALDH1A1CYP1A2THRB | |
| SCHEMBL9481812 | 0.75 | CYP2A6 (0.58) | CHRNB4CHRNA3ALDH1A1CYP1A2THRB | |
| SCHEMBL3161806 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0984943-B1 | AZACYCLOOCTANE AND HEPTANE DERIVATIVES, THEIR PREPARATION AND USEIN THERAPY | NEUROSEARCH AS (DK) | 2002-12-11 | — | — | EP | claimed |
| EP-0984943-A1 | AZACYCLOOCTANE AND HEPTANE DERIVATIVES, THEIR PREPARATION AND USEIN THERAPY | NEUROSEARCH A/S (DK) | 2000-03-15 | — | — | EP | claimed |
| WO-1998054152-A1 | AZACYCLOOCTANE AND HEPTANE DERIVATIVES, THEIR PREPARATION AND USEIN THERAPY | NEUROSEARCH A/S (DK) | 1998-12-03 | — | — | WO | claimed |
| US-6680314-B2 | USEFUL FOR THE TREATMENT OF DISEASES INVOLVING THE CHOLINERGIC SYSTEM OF THE CENTRAL NERVOUS SYSTEM, PAIN, INFLAMMATORY DISEASES, DISEASES CAUSED BY SMOOTH MUSCLE CONTRACTIONS, LEARNING DEFICIT, COGNITION DEFICIT, ATTENTION DEFICIT | NEUROSEARCH A/S (DK) | 2004-01-20 | — | — | US | disclosed |
| EP-0984943-B1 | AZACYCLOOCTANE AND HEPTANE DERIVATIVES, THEIR PREPARATION AND USEIN THERAPY | NEUROSEARCH AS (DK) | 2002-12-11 | — | — | EP | disclosed |
| US-20020169156-A1 | Azacyclooctane and heptane derivatives, their preparation and use in therapy | NEUROSEARCH A/S | 2002-11-14 | — | — | US | disclosed |
| US-6420395-B1 | DISORDERS OR DISEASES INVOLVING THE CHOLINERGIC SYSTEM OF THE CENTRAL NERVOUS SYSTEM, PAIN, INFLAMMATORY DISEASES, DISEASES CAUSED BY SMOOTH MUSCLE CONTRACTIONS AND AS ASSISTANCE IN THE CESSATION OF CHEMICAL SUBSTANCE ABUSE. | NEUROSEARCH A/S (DK) | 2002-07-16 | — | — | US | disclosed |
| EP-0984943-A1 | AZACYCLOOCTANE AND HEPTANE DERIVATIVES, THEIR PREPARATION AND USEIN THERAPY | NEUROSEARCH A/S (DK) | 2000-03-15 | — | — | EP | disclosed |
| WO-1998054152-A1 | AZACYCLOOCTANE AND HEPTANE DERIVATIVES, THEIR PREPARATION AND USEIN THERAPY | NEUROSEARCH A/S (DK) | 1998-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020169156-A1 | Azacyclooctane and heptane derivatives, their preparation and use in therapy | CHRNA1, CHRNB1, CHRNA3 | CHRNB4 31/4885CHRNA3 3/4885ALDH1A1 838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.